Diffuse Large B Cell Lymphoma Clinical Trial
— COALITIONOfficial title:
A Multicentre Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
Verified date | August 2023 |
Source | Peter MacCallum Cancer Centre, Australia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label, multi-centre, phase Ib/II, parallel arm study evaluating the safety and tolerability of glofitamab in addition to backbone chemotherapy consisting of R-CHOP or polatuzumab vedotin-RCHP for younger patients with higher-risk Diffuse Large B-cell Lymphoma or High Grade B-Cell Lymphoma.
Status | Active, not recruiting |
Enrollment | 80 |
Est. completion date | July 2025 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Age =18yo and =65yo at the time of signing consent 2. Have a histologically confirmed diagnosis of one of the following, according to the 2016 WHO classification: 1. DLBCL, NOS or DLBCL arising as a result of transformation of an indolent lymphoma 2. HGBL, NOS 3. HGBL with rearrangements of MYC and BCL2 and/or BCL6 3. For DLBCL, and HGBL, NOS meets one of the following risk criteria: a. NCCN-IPI of =4 or IPI =3 (appendix 1 and 3) 4. Considered fit for 6 cycles of full dose R-CHOP chemotherapy, as per the Investigator 5. ECOG performance status (appendix 5) of: 1. 0-2 inclusive or 3 if directly attributable to lymphoma for patients entering the trial prior to cycle 1 of R-CHOP 2. 0-1 inclusive for patients entering the trial at cycle 2 6. Patients must be treatment-naïve or have received a maximum of one cycle of full-dose R-CHOP chemotherapy (with or without a steroid pre-phase) 7. Able to provide an archival pre-treatment biopsy. 8. Have measurable disease on a pre-chemotherapy PET/CT, defined as at least one bi-dimensionally measurable nodal lesion of >1.5cm in longest dimension, or at least one bi-dimensionally measurable extranodal lesion of >1.0cm in longest dimension 9. Life expectancy (in the opinion of the Investigator) of = 18 weeks 10. Adequate haematological function 11. Adequate renal function 12. Adequate hepatic function 13. Negative serologic or PCR test results for active acute or chronic HBV infection. 14. Non-haematological AEs from prior anti-cancer therapy must have resolved to Grade =1 (with the exception of alopecia and inclusion criteria 10-12) 15. Negative test results for HCV and HIV. Exclusion Criteria: 1. Inability to comply with protocol mandated hospitalisations and restrictions 2. Prior systemic treatment of an underlying indolent lymphoma with an anthracycline-containing regimen 3. Richter's syndrome 4. Patients with known CNS involvement by lymphoma 5. With the exception of rituximab, any prior treatment with systemic immunotherapeutic agents, including, but not limited to, radio-immuno-conjugates, antibody-drug conjugates, immune/cytokines, and monoclonal antibodies within 4 weeks or five half-lives of the drug, whichever is shorter, before the first dose of study drug 6. With the exception of CHOP used as a first cycle of lymphoma treatment, any chemotherapeutic agent, or treatment with any other investigational agent within 4 weeks prior to study treatment 7. Prior solid organ transplantation 8. Prior autologous or allogeneic stem cell transplantation 9. A history of treatment-emergent immune related AEs associated with prior immunotherapeutic agents 10. Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease 1. Note: patients with a history of stroke who have not experienced a stroke or transient ischaemic attack in the past 2 years are allowed 2. Note: patients with a history of epilepsy who have not experienced a seizure in the past 2 years are allowed, so long as continuation of any ongoing established pharmacologic treatment is not contraindicated 11. Past history of confirmed progressive multifocal leukoencephalopathy 12. Past history of chronic active EBV or HLH 13. Major surgery or significant traumatic injury <28 days prior to study treatment or anticipation of the need for major surgery during study treatment 14. Significant cardiovascular disease, defined as: 1. A left ventricular ejection fraction (as determined by nuclear gated blood pool scan or echocardiogram) <50% 2. Myocardial infarction or unstable angina within the past 6 months 3. Unstable arrhythmia 4. Any other cardiac illness that, in the opinion of the Investigator or CPI, makes the patient unsuitable for anthracycline containing therapy 15. Significant pulmonary disease, including but not limited to clinically significant obstructive pulmonary disease or history of bronchospasm 16. Current grade >1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease 17. Known clinically significant liver disease, including active viral or other hepatitis, current alcohol abuse, or cirrhosis 18. Administration of a live, attenuated vaccine within 4 weeks before study treatment note: influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine at any time during the study treatment period 19. History of other active malignancy within 5 years prior to registration, with the exception of: 1. FL or MZL, previously untreated, or treated with no more than one line of therapy which must not have contained an anthracycline 2. Basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix 3. Prior malignancy treated with a curative intent that has remained in remission without treatment for =2 years prior to registration 20. Patients with known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of the nail beds) at registration a. Note: Patients with latent tuberculosis are excluded 21. Other significant life-threatening illness or medical condition which, in the Investigator's opinion, could compromise the patient's safety, interfere with absorption or metabolism of study drug, affect compliance with the protocol or interpretation of results, or put the study outcomes at undue risk 22. Major contraindication to any of the individual components of the chemotherapy backbone (R, C, H, O, Polatuzumab vedotin, prednisolone) 23. Patients who are pregnant or breastfeeding Other protocol-defined inclusion and exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Box Hill Hospital | Box Hill | Victoria |
Australia | Concord Repatriation General Hospital | Camperdown | New South Wales |
Australia | St Vincent's Public Hospital Sydney | Darlinghurst | New South Wales |
Australia | Barwon Health | Geelong | Victoria |
Australia | Royal Brisbane and Women's Hospital | Herston | Queensland |
Australia | Cabrini Hospital | Malvern | Victoria |
Australia | Alfred Hospital | Melbourne | Victoria |
Australia | Epworth Healthcare | Melbourne | Victoria |
Australia | Peter MacCallum Cancer Centre | Melbourne | Victoria |
Australia | St Vincent's Hospital Melbourne | Melbourne | Victoria |
Australia | Sir Charles Gairdner Hospital | Nedlands | Western Australia |
Australia | Calvary Mater Newcastle | Newcastle | New South Wales |
Australia | Prince of Wales Hospital | Randwick | New South Wales |
Australia | Princess Alexander Hospital | Woolloongabba | Queensland |
Lead Sponsor | Collaborator |
---|---|
Peter MacCallum Cancer Centre, Australia | Hoffmann-La Roche |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Correlation between circulating tumour DNA detection and response (CR and ORR) | From start of treatment till end of study assessed up to 60 months | ||
Other | Comparison of efficacy (rates of CR, ORR, DOR, PFS and OS) between the two study arms | From start of treatment till end of study assessed up to 60 months | ||
Primary | To assess safety of the combination of glofitamab and R-CHOP or pola-RCHP according to number of participants with treatment-related adverse events | From start of treatment till the end of study, assessed up to approximately 60 months | ||
Primary | To evaluate the Relative Dose Intensity (RDI) of the chemotherapy backbone | From start of study treatment till the end of study treatment, assessed up to approximately 12 months | ||
Primary | To evaluate the rates of early chemotherapy discontinuation | From start of study treatment till the end of study treatment, assessed up to approximately 12 months | ||
Secondary | To estimate the proportion of patients achieving a complete response (CR) after cycles 2, 4 and at end of induction treatment (6 cycles) of the novel combination therapy according to Lugano 2014 criteria | Up to approximately 6 months (each cycle is 21 days) | ||
Secondary | To estimate overall response rate (ORR) | Up to approximately 6 months (each cycle is 21 days) | ||
Secondary | To describe progression free survival (PFS) | From first dose of chemotherapy induction to first date of objectively documented progressive disease or date of death of any cause, whichever occurs first, assessed up to approximately 60 months | ||
Secondary | To describe the duration of response (DoR) measured in the subset of patients who achieved CR or PR | Time from the first documented disease response to the date of progressive disease or death, whichever occurs first, assessed up to approximately 60 months | ||
Secondary | Overall survival (OS) as defined as the time from first dose of chemotherapy induction to the date of death from any cause | From first dose of chemotherapy induction to the date of death from any cause, assessed up to approximately 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04670029 -
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
|
Phase 3 | |
Active, not recruiting |
NCT04572763 -
Copanlisib Plus Venetoclax in R/R DLBCL
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04526834 -
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Recruiting |
NCT05365659 -
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
Completed |
NCT03287817 -
CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05645744 -
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
|
||
Completed |
NCT04316624 -
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04555811 -
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
|
Phase 1 | |
Terminated |
NCT04189952 -
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
|
Phase 2 | |
Recruiting |
NCT01949818 -
Treatment of Diffuse Large B Cell Lymphoma
|
Phase 4 | |
Completed |
NCT01459887 -
Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma
|
Phase 3 | |
Completed |
NCT03242902 -
To Decrease Fatigue With Light Therapy
|
Phase 3 | |
Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT05018520 -
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
|
Phase 3 | |
Withdrawn |
NCT04052061 -
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05020392 -
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05006716 -
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 |